IDH2 and astrocytoma (excluding glioblastoma): However, Shirahata et al., Appay et al., and Yoda et al. proposed using CDKN2A/B alone as a molecular marker for grade 4 IDH-mutant astrocytoma, determined by a number of methods, including methylation, SNP array, and NGS [11,12,13].